Astrazeneca (AZN) stock closed at $79.76, up 1.49% from the previous day, outperforming the S&P 500’s 1.39% loss. The company’s shares have increased by 0.22% in the last month, lower than the Medical sector’s gain of 1.98%. Analysts predict a 11.11% decline in EPS for the upcoming earnings report on July 25, 2024.

Astrazeneca’s consensus estimates forecast earnings of $4.05 per share and revenue of $51.95 billion for the year, up 11.57% and 13.41% respectively. Recent analyst revisions could impact the stock’s performance. The Zacks Rank system rates AZN as a #3 (Hold) stock with a +0.33% increase in EPS estimate over the past month.

Astrazeneca’s valuation shows a Forward P/E ratio of 19.41, higher than the industry average of 14.98, with a PEG ratio of 1.41. The company’s industry, Large Cap Pharmaceuticals, ranks in the bottom 36% of all industries. To track AZN’s performance, utilize Zacks.com for more information on the stock.

Get 30-day access to all Zacks’ picks for just $1. Explore portfolio services like Surprise Trader and Technology Innovators for potential gains. Don’t miss out on this opportunity to access top stock recommendations and maximize your investment potential with Zacks Investment Research.

Read more at Nasdaq: Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts